Novo Holdings REPAIR Impact Fund supports upsized MinervaX EUR 47.4M Series B financing to advance novel vaccine against Group B Streptococcus
Novo Holdings REPAIR Impact Fund supports upsized MinervaX EUR 47.4M Series B financing to advance novel vaccine against Group B Streptococcus
12/15/20, 8:29 AM
Location
copenhagenMoney raised
$4 million
Round Type
series b
Today, the Novo Holdings REPAIR Impact Fund announces a further investment in MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), renewing its commitment to the company following two tranches of investment in 2018 and 2019. Initial investment in MinervaX was from Novo Seeds, and has since been supported by the Novo Holdings REPAIR Impact Fund. The new investment is part of an upsized EUR 47.4 Million series B financing round additionally supported by new investors, Sanofi Ventures, Wellington Partners, Adjuvant Capital, Industrifonden and existing investor Sunstone Life Science Ventures and LF Investment. Proceeds will advance the clinical development of MinervaX's novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.
Company Info
Location
copenhagen, capital region of denmark, denmark
Additional Info
The Fund invests in start-ups, early-stage companies and corporate spin-outs around the world. It gives priority to first-in-class therapies, covering small molecules, biologics and new modalities, from the early stage of drug development (lead optimization) to later stages of clinical development (into Phase 2). It can invest as the sole investor or in a syndicate, with investments ranging from EUR 1 million to EUR 12 million.